Tebentafusp in Uveal Melanoma: NCT07276386 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Recruiting
Recruitment status
18
Planned enrollment
2030-12-01
Primary-completion proxy
Executive view
NCT07276386 evaluates Tebentafusp in Uveal Melanoma. The disclosed sponsor is H. Lee Moffitt Cancer Center & Research Institute, Inc., the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Progression Free Survival (PFS), assessed over Up to 24 months.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07276386 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Uveal Melanoma landscape. Drug & Asset MCP drug_fetch was queried for Tebentafusp, while Company & Deal Intelligence MCP organization_fetch was queried for H. Lee Moffitt Cancer Center & Research Institute, Inc..
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07276386 | Tebentafusp | Phase 2 / Recruiting | H. Lee Moffitt Cancer Center & Research Institute, Inc. | United States | Progression Free Survival (PFS) Up to 24 months | 2030-12-01 |
| NCT07280832 | SYS-6090 | Phase 1/2 / Recruiting | Shanghai JMT Biological Technology Co Ltd | China | Dose-Limiting Toxicity (DLT) (Phase I) Approximately 28 days. | 2026-11-30 |
| NCT07260591 | VSV-02 | Phase 1 / Recruiting | The First Affiliated Hospital of Xinxiang Medical College | China | Objective Response Rate (ORR) From enrollment until the first occurrence of disease progression or… | 2026-09-30 |
| NCT07252479 | AN-9025 | Phase 1 / Recruiting | Hangzhou Adlai Nortye Biopharma Co. Ltd. | United States | • Nature and frequency of dose limiting toxicities (DLTs) 21 days after first dose | 2028-01-31 |
| NCT07237594 | Secukinumab | Phase 1 / Recruiting | Duke University | United States | Safety of administering an IL-17A (human IgG1κ) monoclonal antibody (secukinumab) as determined by occurrence of immune… Until grade 3 side effect occurs or three years, whichever comes first | 2027-06-30 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07276386 is a Phase 2, recruiting study with 18 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Progression Free Survival (PFS)” over “Up to 24 months.” The retrieved endpoint description is: PFS will be studied as time-to-event defined by the first documented disease progression or death due to any cause, whichever occurs first, from the start date of the study treatment. PFS will be determined based on tumor assessment (RECIST version 1.1 criteria)..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 18 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Uveal Melanoma. These records do not establish direct evidence for NCT07276386 unless the registration number matches.
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma
Phase 2; n=30; AE(Grade 3 and higher) = 50.0 % Source: https://pubmed.ncbi.nlm.nih.gov/41732954/
A Phase II Study to Evaluate the Safety and Efficacy of Rigosertib (ON 01910) Plus Pembrolizumab in Patients With Metastatic Melanoma Refractory to Immune Checkpoint Blockade
Phase 2; n=7; ORR = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05764395
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to PD-1…
Phase 2; n=23; CR = 0 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04796194
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Tebentafusp is indexed as Bispecific T-cell Engager (BiTE) with CD3 x gp100 biology and a global stage of Approved. The asset profile lists Immunocore Ltd. as an originator or developer.
H. Lee Moffitt Cancer Center & Research Institute, Inc. is indexed in United States with the website http://www.moffitt.org. Provides research & contributions to clinical trials, prevention and cancer control The record lists 55 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Tebentafusp is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07276386
Protocol source: https://clinicaltrials.gov/study/NCT07276386
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Tebentafusp in Uveal Melanoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Progression Free Survival (PFS) and 2030-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
